141 related articles for article (PubMed ID: 18653575)
1. Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons: randomised controlled trial.
Flammer AJ; Vo NT; Ledergerber B; Hermann F; Gämperli A; Huttner A; Evison J; Baumgartner I; Cavassini M; Hayoz D; Quitzau K; Hersberger M; Sudano I; Ruschitzka F; Lüscher TF; Noll G; Weber R
Heart; 2009 Mar; 95(5):385-90. PubMed ID: 18653575
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
[TBL] [Abstract][Full Text] [Related]
3. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
[TBL] [Abstract][Full Text] [Related]
5. Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjects.
Guffanti M; Caumo A; Galli L; Bigoloni A; Galli A; Dagba G; Danise A; Luzi L; Lazzarin A; Castagna A
Eur J Endocrinol; 2007 Apr; 156(4):503-9. PubMed ID: 17389467
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia.
Lu CL; Lin YH; Wong WW; Lin HH; Ho MW; Wang NC; Hsieh SM; Sheng WH; Hung CC; Chen MY
J Microbiol Immunol Infect; 2011 Aug; 44(4):258-64. PubMed ID: 21524961
[TBL] [Abstract][Full Text] [Related]
7. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study).
Di Giambenedetto S; Fabbiani M; Colafigli M; Ciccarelli N; Farina S; Sidella L; D'Avino A; Mondi A; Cingolani A; Tamburrini E; Murri R; Navarra P; Cauda R; De Luca A
J Antimicrob Chemother; 2013 Jun; 68(6):1364-72. PubMed ID: 23372058
[TBL] [Abstract][Full Text] [Related]
8. [HIV infection, antiretroviral therapy, and endothelium].
Hürlimann D; Weber R; Enseleit F; Lüscher TF
Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
[TBL] [Abstract][Full Text] [Related]
9. Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy.
Murphy RL; Berzins B; Zala C; Fichtenbaum C; Dube MP; Guaraldi G; Torriani F; Belsey E; Mitchell C; Stein JH;
AIDS; 2010 Mar; 24(6):885-90. PubMed ID: 19952712
[TBL] [Abstract][Full Text] [Related]
10. Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir.
Sension M; Andrade Neto JL; Grinsztejn B; Molina JM; Zavala I; González-García J; Donnelly A; Phiri P; Ledesma E; McGrath D;
J Acquir Immune Defic Syndr; 2009 Jun; 51(2):153-62. PubMed ID: 19346966
[TBL] [Abstract][Full Text] [Related]
11. Endothelial function in HIV-infected patients switching from a boosted protease inhibitor-based regimen to raltegravir: a substudy of the SPIRAL study.
Masiá M; Martínez E; Padilla S; Gatell JM; Gutiérrez F
J Antimicrob Chemother; 2013 Feb; 68(2):409-13. PubMed ID: 23075691
[TBL] [Abstract][Full Text] [Related]
12. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects.
Sanne I; Piliero P; Squires K; Thiry A; Schnittman S;
J Acquir Immune Defic Syndr; 2003 Jan; 32(1):18-29. PubMed ID: 12514410
[TBL] [Abstract][Full Text] [Related]
13. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
[TBL] [Abstract][Full Text] [Related]
14. A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity.
Moyle GJ; Andrade-Villanueva J; Girard PM; Antinori A; Salvato P; Bogner JR; Hay P; Santos J; Astier L; Pans M; Balogh A; Biguenet S;
Antivir Ther; 2012; 17(4):689-700. PubMed ID: 22388634
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
Pavie J; Porcher R; Torti C; Medrano J; Castagna A; Valin N; Rusconi S; Ammassari A; Ghosn J; Delaugerre C; Molina JM;
J Antimicrob Chemother; 2011 Oct; 66(10):2372-8. PubMed ID: 21821627
[TBL] [Abstract][Full Text] [Related]
16. Endothelial dysfunction, increased inflammation, and activated coagulation in HIV-infected patients improve after initiation of highly active antiretroviral therapy.
Arildsen H; Sørensen KE; Ingerslev JM; Østergaard LJ; Laursen AL
HIV Med; 2013 Jan; 14(1):1-9. PubMed ID: 22639788
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir.
Gianotti N; Seminari E; Guffanti M; Boeri E; Villani P; Regazzi M; Bigoloni A; Schira G; Tiberi S; Fusetti G; Lazzarin A; Castagna A
New Microbiol; 2005 Apr; 28(2):119-25. PubMed ID: 16035256
[TBL] [Abstract][Full Text] [Related]
18. Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients.
Naeger LK; Struble KA
AIDS; 2006 Apr; 20(6):847-53. PubMed ID: 16549968
[TBL] [Abstract][Full Text] [Related]
19. Serum adiponectin and metabolic parameters in HIV-1-infected patients after substitution of nevirapine for protease inhibitors.
Petit JM; Duong M; Masson D; Buisson M; Duvillard L; Bour JB; Brindisi MC; Galland F; Guiguet M; Gambert P; Portier H; Vergès B
Eur J Clin Invest; 2004 Aug; 34(8):569-75. PubMed ID: 15305892
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen.
Colafigli M; Di Giambenedetto S; Bracciale L; Tamburrini E; Cauda R; De Luca A
HIV Med; 2008 Mar; 9(3):172-9. PubMed ID: 18217998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
